ECM
RCKT icon

Evergreen Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Evergreen Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,468
Closed -$41.1K – 1648
2026
Q1 		$41.1K Sell
11,468
-1,447
-11% -$5.75K ﹤0.01% 1496
2025
Q4 		$45.3K Buy
+12,915
New +$44.2K ﹤0.01% 1402

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Evergreen Capital Management's RCKT Position: Q2 2026 in Review

Evergreen Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 11,468 shares — an estimated $41.1K sold.

Evergreen Capital Management first reported a position in RCKT in Q4 2025 and held it in 2 quarters. The position peaked at $45.3K in Q4 2025. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Evergreen Capital Management reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Evergreen Capital Management sold 11,468 Rocket Pharmaceuticals shares in Q2 2026, an estimated $41.1K.
  • Evergreen Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Evergreen Capital Management's Rocket Pharmaceuticals position peaked at $45.3K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.